Filtering

DOP01 Exclusive enteral nutrition for the treatment of adult Crohn’s diseaseECCO'20 Vienna
Year: 2020
Authors: D. Shukla, L. Purcell, M. Palmer, L. Pillay

Department of Gastroenterology, Logan Hospital, Brisbane, Australia

DOP02 The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers

ECCO'20 Vienna

Year: 2020
Authors:

V. Svolos1, K. Gkikas1, V. Rizou1, E. Christina1, P. Kapranos1, J. Kleingunnewiek1, J.P. Seenan2, J. Macdonald2, D.R. Gaya3, R. Hansen4, R.K. Russell4, K. Gerasimidis1

1Department of Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK, 2Department of Gastroenterology, Queen Elizabeth University Hospital, Glasgow, UK, 3Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK, 4Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, UK

DOP03 The impact of elemental diet on the human gut microbial structure and intestinal metabolites

ECCO'20 Vienna

Year: 2020
Authors:

J. Miyoshi1, D. Saito1, M. Nakamura2, M. Miura1, T. Mitsui1, T. Kudo3, S. Murakami3, M. Matsuura1, T. Hisamatsu1

1Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka-shi, Japan, 2Nutrition Department, Kyorin University Hospital, Mitaka-shi, Japan, 3Metabologenomics Inc., n/a, Tsuruoka-shi, Japan

DOP04 Matching between donors and patients in faecal microbiota transplantation is important for long-term maintenance on ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

D. Ishikawa PhD, K. Okahara, M. Takahashi, K. Haga, K. Nomura, T. Shibuya, A. Nagahara

Department of Gastroenterology, Juntendo University, Tokyo, Japan

DOP05 Perioperative Dietary Therapy in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

M. Adamina1, K. Gerasimidis2, R. Sigall-Boneh3,4, O. Zmora5, A. de Buck van Overstraeten6,7, M. Campmans-Kuijpers8, P. Ellul9, K. Katsanos10, P. Kotze11, N. Noor12, J. Schäfli-Thurnherr13, S. Vavricka13, C. Wall14, N. Wierdsma15, N. Yassin16, M. Lomer17, ECCO Topical Review on Perioperative Dietary Therapy in Inflammatory Bowel Disease

1Department of Visceral and Thoracic Surgery, Kantonsspital Winterthur, Winterthur, Switzerland, 2Department of Human Nutrition, Glasgow Royal Infirmary, School of Medicine, Dentistry and Nursing, Glasgow, UK, 3Pediatric Gastroenterology and Nutrition Unit, Wolfson Medical Center, PIBD Research Center, Holon, Israel, 4Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 5Department of Surgery, Assaf Harofeh Medical Center, Tel Aviv, Israel, 6Department of Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada, 7Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Canada, 8Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands, 9Department of Medicine, Division of Gastroenterology, Mater Dei Hospital, Msida, Malta, 10Division of Gastroenterology, University Hospital of Ioannina, Ionnanina, Greece, 11Colorectal Surgery Unit, Catholic University of Paraná, Curitiba, Brazil, 12Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK, 13Department of Surgery, Cantonal Hospital Winterthur, Winterthur, Switzerland, 14Department of Nutritional Sciences, King’s College London, London, UK, 15Department of Nutrition and Dietetics, Amsterdam UMC, location VU University Medical Centre, Amsterdam, The Netherlands, 16Department of Colorectal Surgery, The Royal Wolverhampton Hospitals, Wolverhampton Hospital, Wolverhampton, UK, 17Guy’s and St Thomas’ NHS Foundation Trust and King’s College, London, London, UK

DOP06 Non-invasive identification of adherent-invasive E. coli in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

A. Buisson1, E. Vazeille1, X. Hébuterne2, M. Fumery3, B. Pariente4, S. Nancey5, P. Seksik6, L. Peyrin-Biroulet7, M. Allez8, N. Ballet9, E. Billard10, S. Rodriguez10, B. Pereira11, N. Barnich10, CEALIVE Study Group

1Department of Digestive and Hepatobiliary Medicine, Department of Gastroenterology, CHU Estaing, Clermont-Ferrand, France, 2CHU Nice, Department of Gastroenterology, Nice, France, 3Department of Gastroenterology, CHu Amiens, Amiens, France, 4Department of Gastroenterology, CHU Lille, Lille, France, 5Department of Gastroenterology, CHU Lyon-Sud, Lyon, France, 6Department of Gastroenterology, CHU Saint-Antoine, Paris, France, 7Department of Gastroenterology, CHU Nancy, Nancy, France, 8Department of Gastroenterology, Saint-Louis Hospital, Paris, France, 9Lesafre Company, France, France, 10U1071 Inserm UCA, M2iSH, Clermont-Ferrand, France, 11CHU, Biostatistics Unit, Clermont-Ferrand, France

DOP07 Long-term results of 4.5 years of faecal microbiota transplantation for treatment of refractory ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Uygun1, M.F. Karakaya1, H. Erdal1, G. Celebi1, Y.S. Sakin1, C. Artuk2, K. Ozturk1, M. Gulsen1

1Department of Gastroenterology, Gulhane Faculty of Medicine, Ankara, Turkey, 2Department of Infectious Diseases and Clinical Microbiology, Gulhane Faculty of Medicine, Ankara, Turkey

DOP08 Deep remission in paediatric Crohn’s disease is associated with increased abundance of dialister species and increased valerate

ECCO'20 Vienna

Year: 2020
Authors:

H. Taylor1, J. McDonald1, J.I. Serrano Contreras1, J. Li1, J. Marchesi1, A. Hart1,2

1Department of Medicine, Imperial College London, London, UK, 2Inflammatory Bowel Disease Unit, St Mark’s Academic Institute, London, UK

DOP09 IgG responses to multiple bacterial flagellins identify a subgroup of paediatric therapy-naive Crohn’s disease patients with increased microbiota-specific T-cell reactivity

ECCO'20 Vienna

Year: 2020
Authors:

L. Costes1, I. Tindemans1, M.E. Joosse1, M.A. Aardoom2, M.M.E. Jongsma2, R.H.C. Raatgeep1, D.H. van Haaften1, K.L. Alexander3, L.W. Duck3, A.P. Heikema4, P. Kemos5, J.C. Escher2, F.M. Ruemmele6, N.M. Croft7, C.O. Elson8, L. de Ridder2, J.N. Samsom1

1Laboratory of Pediatrics, Division Gastroenterology and Nutrition, Erasmus University Medical Center, Sophia Children’s Hospital, Rotterdam, The Netherlands, 2Department of Pediatric Gastroenterology, Erasmus University Medical Center, Sophia Children’s Hospital, Rotterdam, The Netherlands, 3Departments of Immunology, University of Alabama at Birmingham, Birmingham, USA, 4Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands, 5Blizard Institute, Queen Mary University of London, London, UK, 6Service de Gastroentérologie, Sorbonne Paris Cité- APHP, Hôpital Necker Enfants Malades, Université Paris Descartes, Paris, France, 7Centre for Digestive Diseases, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK, 8Department of Medicine, University of Alabama at Birmingham, Birmingham, USA

DOP10 Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy

ECCO'20 Vienna

Year: 2020
Authors:

T. Kucharzik1, R. Wilkens2,3, G. Maconi4, M.A. D’Agostino5, M. Le Bars6, M. Nazar7, S. Sloan8, M. Lahaye9, L. Ni10, E. Ercole11, M. Alloca12, N. Machková13, C. Maaser14

1Klinik für Allgemeine Innere Medizin und Gastroenterologie, Klinikum Lüneburg, Lüneburg, Germany, 2Gastro Unit Section of Medicine, Hvidovre Hospital, Copenhagen, Denmark, 3Digestive Disease Center, Bispebjerg Hospital, Copenhagen, Denmark, 4Gastroenterology Unit, Department of Biomedical and Clinical Sciences, ‘Luigi Sacco’ University Hospital University of Milan, Milan, Italy, 5Ambroise Paré Hospital APHP-Paris Saclay, University INSERM U1173 Laboratoire d’Excellence INFLAMEX, Rheumatology Department, Paris, France, 6Department of Medical Affairs, Janssen-Cilag SARL, Issy-les-Moulineaux, France, 7Department of Medical Affairs, Janssen-Cilag Polska Sp. z o.o, Warsaw, Poland, 8Department of Medical Affairs, Janssen Scientific Affairs LLC, Horsham, PA, USA, 9Department of Medical Affairs, Janssen-Cilag B.V., Breda, The Netherlands, 10Department of Medical Affairs, Janssen-Cilag, Moscow, Russian Federation, 11Gastroenterology Unit, Mauriziano Hospital, Turin, Italy, 12Department of Gastroenterology, Humanitas University, Milan, Italy, 13Clinical Center ISCARE, Clinical and Research Center for Inflammatory Bowel Diseases, Prague, Czech Republic, 14Ambulanzzentrum Gastroenterologie, Klinikum Lüneburg, Lüneburg, Germany

DOP11 Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

N. Plevris, J. Fulforth, P. Jenkinson, M. Lyons, C. Chuah, S. Siakavellas, R. Pattenden, I. Arnott, G. Jones, C. Lees

The Edinburgh IBD Unit, Gastroenterology, Western General Hospital, Edinburgh, UK

DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension

ECCO'20 Vienna

Year: 2020
Authors:

R. Panaccione1, W.J. Sandborn2, B.E. Sands3, C. Marano4, C.D. O’Brien4, H. Zhang5, J. Johanns5, Y. Zhou5, L. Peyrin-Biroulet6, T. Hisamatsu7, S. Danese8, UNIFI Investigators

1University of Calgary, Inflammatory Bowel Disease Center, Calgary, Canada, 2University of California San Diego, Gastroenterology, La Jolla, USA, 3Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, USA, 4Janssen Research and Development- LLC, Immunology, Spring House, USA, 5Janssen Research and Development- LLC, Clinical Biostats, Spring House, USA, 6Nancy University Hospital, Gastroenterology, Nancy, France, 7Kyorin University School of Medicine, Internal Medicine, Tokyo, Japan, 8Humanitas Research Hospital, Gastroenterology, Milan, Italy

DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial

ECCO'20 Vienna

Year: 2020
Authors:

S. Danese1, S. Vermeire2, G. D’Haens3, J. Panés4, A. Dignass5, F. Magro6, M. Nazar7, M. Le Bars8, S. Sloan9, M. Lahaye10, L. Ni11, M. Daperno12, M. Lukáš13, A. Armuzzi14, M. Löwenberg3, D.R. Gaya15, L. Peyrin-Biroulet16

1Humanitas University, Department of Gastroenterology, Milan, Italy, 2University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 3University of Amsterdam, Academic Medical Centre, Amsterdam, The Netherlands, 4Hospital Clinic of Barcelona CIBERehd, Department of Gastroenterology, Barcelona, Spain, 5Agaplesion Markus Hospital, Department of Medicine I, Frankfurt/Main, Germany, 6Department of Pharmacology and Therapeutics, Institute for Molecular and Cell Biology, Faculty of Medicine, University of Porto, and Department of Gastroenterology, Hospital de Sao Joao, Porto, Portugal, 7Janssen-Cilag Polska Sp. z o.o, Medical Affairs, Warsaw, Poland, 8Janssen-Cilag, Medical Affairs, Issy-les-Moulineaux, France, 9Janssen Global Services LLC, Medical Affairs, Horsham, PA, USA, 10Janssen-Cilag B.V., Medical Affairs, Breda, The Netherlands, 11Janssen-Cilag Russia, Medical Affairs, Moscow, Russian Federation, 12Mauriziano Hospital, Gastroenterology Unit, Turin, Italy, 13Clinical Center ISCARE, Clinical and Research Center for Inflammatory Bowel Diseases, Prague, Czech Republic, 14Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore, IBD Unit Presidio Columbus, Rome, Italy, 15Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, UK, 16University Hospital of Nancy University of Lorraine, INSERM Unité 954 and Department of Hepato-Gastroenterology, Houdemont, France

DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

E. Dreesen1, S. Berends2, D. Laharie3, G. D’Haens4, S. Vermeire5, A. Gils1, R. Mathôt2

1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 2Department of Hospital Pharmacy, Amsterdam UMC, Amsterdam, The Netherlands, 3Hepato-gastroenterology and Digestive Oncology, Haut-Lévêque Hospital- Bordeaux UMC, Bordeaux, France, 4Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands, 5Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

DOP15 Transmural healing with vedolizumab in patients with active Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

J. Rimola1, J.F. Colombel2, B. Bressler3, S. Adsul4, J. Siegelman5, P.E. Cole6, D. Lindner7, S. Danese8

1Department of Radiology, Hospital Clínic de Barcelona, Barcelona, Spain, 2Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, USA, 3Division of Gastroenterology-, University of British Columbia, Vancouver, Canada, 4Takeda, Global Medical Affairs, Zurich, Switzerland, 5Clinical Development and Clinical Translation, Takeda, Cambridge, USA, 6Takeda, Department of Imaging, Cambridge, USA, 7Takeda, Statistical and Quantitative Sciences, Zurich, Switzerland, 8Department of Gastrointestinal Immunopathology, Humanitas University, Milan, Italy

DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2

ECCO'20 Vienna

Year: 2020
Authors:

C. Chen1, M. Rosario2, D. Polhamus3, N. Dirks3, W. Zhang4, W. Sun1, K. Kisfalvi5, B. Feagan6, W. Sandborn7, S. Vermeire8, G. D’Haens9

1Takeda, Quantitative Clinical Pharmacology, Cambridge, USA, 2Takeda, Clinical Pharmacology, Deerfield, USA, 3Metrum Research Group, Tariffville, USA, 4Takeda, Statistical and Quantitative Sciences, R&D, Cambridge, USA, 5Takeda, Research and Development, Global Clinical Sciences, Cambridge, USA, 6Western University, Robarts Clinical Trials, London, Ontario, Canada, 7Division of Gastroenterology, University of California San Diego, La Jolla, USA, 8Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, 9Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, The Netherlands

DOP17 Identification of biomarkers and mechanistic insight for upadacitinib in ulcerative colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study

ECCO'20 Vienna

Year: 2020
Authors:

S. Vermeire1, H. Guay2, B. Verstockt3, J. Fann4, J. Cheng4, F. Hong4, W.J. Lee5, A. Lacerda6, W. Zhou6, S. Danese7

1Department of Translational Research Centre for GastroIntestinal Disorders TARGID, KU Leuven, Leuven, Belgium, 2Immunology Clinical Development, AbbVie Inc., Worcester, USA, 3Department of Chronic Diseases, Metabolism and Ageing, CHROMETA, KU Leuven, Leuven, Belgium, 4Discovery and Exploratory Statistics, AbbVie Inc., Worcester, USA, 5Health Economics and Outcomes Research HEOR, AbbVie Inc., Worcester, USA, 6Global Pharmaceutical Research and Development, AbbVie Inc., North Chicago, USA, 7Department of Gastroenterology, Instituto Clinico Humanitas, Milan, Italy

DOP18 Impact of adherence to anti-tumour necrosis factor therapy on clinical outcomes in Crohn’s disease: A nationwide population-based study

ECCO'20 Vienna

Year: 2020
Authors:

J.J. Park1, H. Koo2, Y. Park1, S.J. Park1, T.I. Kim1, W.H. Kim1, J.H. Cheon1, E.H. Han2

1Severance Hospital, Internal Medicine, Seoul, Korea Republic of, 2Yonsei Institute of Pharmaceutical Sciences, Yonsei University, College of Pharmacy, Incheon, Korea Republic of

DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months

ECCO'20 Vienna

Year: 2020
Authors:

B. Cohen1, H. Chang2, J.R. Jason Rogers1, S. Garg1, D. Lawrence3, F. Fasihuddin1, T. Lissoos4, A. Atreja5

1Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA, 2Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA, 3Department of Gastroenterology, Takeda Pharmaceuticals, Deerfield, USA, 4Lilly Biomedicines, Eli Lilly & Company, Indianapolis, USA, 5Department of Gastroenterology, Mount Sinai, New York, USA

DOP20 Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine

ECCO'20 Vienna

Year: 2020
Authors:

R.C.A. Lalisang1, G. Adriaans2, M. de Jong3, A. van der Meulen-de Jong4, M. Romberg-Camps5, N. Mahmmod6, T. Markus-de Kwaadsteniet7, G. Dijkstra8, J. Haans2, C. Stamm9, R. Vanwersch10, D. Jonkers11, R.J. Almeida12,13, M.J. Pierik2, MyIBDcoach Study Group

1Division of Gastroenterology and Hepatology, Maastricht Universitair Medisch Centrum+, Pacmed, Maastricht, The Netherlands, 2Division of Gastroenterology and Hepatology, Maastricht Universitair Medisch Centrum+, Maastricht, The Netherlands, 3Haga Ziekenhuis, Department of Gastroenterology, Den Haag, The Netherlands, 4Department of Gastroenterology, Leiden University Medical Center, Leiden, The Netherlands, 5Department of Gastroenterology, Zuyderland Medical Centre, Sittard, The Netherlands, 6Department of Gastroenterology, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands, 7Stichting mijnIBDcoach, Board, Mijdrecht, The Netherlands, 8Department of Gastroenterology, Universitair Medisch Centrum Groningen, Groningen, The Netherlands, 9Department of Health Care, Pacmed, Amsterdam, The Netherlands, 10Information Systems, Faculty of Industrial Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands, 11Department of Internal Medicine, Division of Gastroenterology-Hepatology, University Maastricht, Maastricht, The Netherlands, 12Department of Quantitative Economics, School of Business and Economics, Maastricht University, Maastricht, The Netherlands, 13Department of Data Analytics and Digitalisation, Maastricht University, Maastricht, The Netherlands